CEO Terry Rosen sold 54,691 shares (54.7K) for $1.2M across 2 sales at blended $22.01; stock up +77.5% in 90 days
Terry Rosen, CEO of Arcus Biosciences, executed 2 separate sales totaling 54,691 shares for $1,203,959.00 on 2025-12-16 and 2025-12-17, reducing his position by 2.4% to 2,194,809 shares post-transaction. The sales occurred as the stock traded at the blended price of $22.01, following a sharp +77.5% gain over the prior 90 days and within 15.8% of its 52-week high of $26.10. While the company is unprofitable (net income of $-135,000,000.00 on quarterly revenue of $26,000,000.00), it is experiencing strong annual revenue growth of +120.5%. His sole prior trade at this ticker (a February 2025 buy) showed negative 90-day returns of -10.3%, and his cross-ticker track record exhibits a 0% win rate on buys with average 90-day returns of -10.3%, though this timing does not apply to his current sell activity. The timing of this sale relative to the stock's recent 77.5% surge and proximity to all-time highs warrants examination against his historical execution pattern.